mice trial Sanofi concluded that the use of our C1 platform
resulted in equal or better influenza protection, using a lower
amount of vaccine that could be produced at 10-30 times
higher productivity levels.

The Original Sanofi Presentation can be found at the following
link:

https://www.dyadic.com/wp-content/uploads/2018/01/Sanofi-
Pasteur-C 1-Presentation.pdf

 

Working together we can “Keep America Safe’ by helping
to address the immediate coronavirus outbreak, be better
prepared for future infectious diseases, pandemic, and
epidemic outbreaks, and leveraging this unfortunate situation to
advance biopharmaceutical manufacturing to help speed
development, lower the cost and improve the performance of

NIH-000608
